Abstract
Abstract
Purpose
To investigate whether ProVate™, a novel, disposable, self-inserted vaginal device for pelvic organ prolapse management, clinically affects the vaginal microflora, as compared with a commercially available ring pessary, in order to assess its microbiological safety.
Methods
This interventional, prospective, multi-center, open-label, randomized, controlled, statistically powered (non-inferiority), home-use, cross-over study was conducted at seven sites. Participants were randomized into either group A (using ProVate™ and then a new reusable commercially available ring pessary [control]) or B (using control device and then ProVate™) with a 1:1 ratio. Primary endpoint was based on meeting one of the failure criteria: significant change in Lactobacillus spp., Gardnerella vaginalis, Candida morphotypes, or Staphylococcus aureus levels compared to the baseline (significant change: Nugent score ≥ 7 or > 1 scale unit increase in S. aureus or Candida morphotype), bothersome vaginal symptoms, or symptoms requiring treatment.
Results
The study included 58 participants (mean age: 64.5 years, 91.4% post-menopausal). The failure rate was 15.5% for ProVate™ and control groups while using 383 ProVate™ devices over 1,647 days or one control device throughout the study. Two patients had bothersome vaginal complaints and one had vaginal infection in the control group, but no such cases were observed in the ProVate™ group.
Conclusion
The primary endpoint of possible vaginal microbial changes, bothersome vaginal symptoms, or treatment-requiring vaginal complaints while using ProVate™ was successfully met. Our findings show that the vaginal microflora is comparable when using either ProVate™ or commercially available ring pessary (control) with a relatively low rate of vaginal infections.
Trial registration details
ClinicalTrials.gov;
Publisher
Research Square Platform LLC
Reference28 articles.
1. International urogynecology consultation Chap. 1 committee 2: epidemiology of pelvic organ prolapse: prevalence, incidence, natural history, and service needs;Brown HW;Int Urogynecol J,2022
2. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050;Wu JM;Obstet Gynecol,2009
3. The role of the nurse in the use of vaginal pessaries to treat pelvic organ prolapse and/or urinary incontinence: a literature review;McIntosh L;Urol Nurs,2005
4. Impact of pessary use on prolapse symptoms, quality of life, and body image;Patel M;Am J Obstet Gynecol,2010
5. Discontinuation rate and adverse events after 1 year of vaginal pessary use in women with pelvic organ prolapse;Yimphong T;Int Urogynecol J,2018